Form 4: RA Capital Sells Over 4.1M FULC Shares

RA Capital Management, a 10% owner and director, reported significant sales of Fulcrum Therapeutics common stock totaling over 4.1 million shares.

Summary

• RA Capital Management, L.P., a 10% owner and director of Fulcrum Therapeutics, Inc. (FULC), reported the sale of 4,175,139 shares of common stock.
• The sales occurred on December 8, 2025, across three separate transactions.
• The first transaction involved 1,377,020 shares at a weighted average price of $13.33, with prices ranging from $12.81 to $13.8099.
• The second transaction involved 2,706,397 shares at a weighted average price of $14.28, with prices ranging from $13.81 to $14.805.
• The third transaction involved 91,722 shares at a weighted average price of $14.98, with prices ranging from $14.81 to $15.39.
• Following these transactions, RA Capital Healthcare Fund LP indirectly holds 6,053,960 shares of Fulcrum Therapeutics common stock.
• The sales were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 3

Explanation: The sentiment is negative due to a significant reduction in stake by a major institutional investor and director, which can signal reduced confidence or a strategic shift away from the company. While the sales were pre-planned under a 10b5-1 plan, the sheer volume of shares sold is a notable negative.

Positives

• The sales were executed at relatively strong price points, ranging from $12.81 to $15.39 per share.
• The transactions were conducted under a Rule 10b5-1 plan, indicating pre-planned sales and potentially reducing concerns about opportunistic selling.

Negatives

• A significant institutional investor and 10% owner, RA Capital Management, has reduced its stake in Fulcrum Therapeutics by over 4.1 million shares.
• Such a large sale by a major shareholder and director could be perceived negatively by the market, potentially signaling a lack of confidence or a strategic portfolio rebalancing away from FULC.

Risks

• Market perception risk: Large insider sales can lead to negative market sentiment and downward pressure on the stock price.
• Liquidity risk: The sale of a substantial block of shares could impact the stock's liquidity if not absorbed smoothly by the market.

Future Outlook

The filing does not contain any explicit forward-looking statements or guidance regarding the company's future performance or strategic direction. It solely reports past insider transactions.

Management Comments

• The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

Industry Context

This Form 4 filing reflects an investment firm's portfolio management decision rather than a direct operational update from Fulcrum Therapeutics. In the biotechnology sector, large institutional investor sales can sometimes precede or follow significant company news, but without additional context from Fulcrum, it's difficult to ascertain a direct link to broader industry trends or competitive positioning. It could simply be a rebalancing of a diversified healthcare fund's holdings.

Comparison to Industry Standards

• This filing reports insider trading activity, which is not directly comparable to industry operational or financial standards. The decision by a 10% owner and director to reduce their stake is an internal investment decision by RA Capital Management.
• While other biotech companies may see similar insider activity, the specific reasons for such sales are unique to each investor's strategy and the company's specific circumstances. There are no specific comparable companies or projects mentioned in the filing to assess against.

Related Party Transactions

• The transactions involve RA Capital Management, L.P., RA Capital Healthcare Fund LP, Peter Kolchinsky, and Rajeev M. Shah, who are identified as 10% owners and directors of Fulcrum Therapeutics. These are considered related party transactions due to their significant ownership and board representation.

Stakeholder Impact

• Shareholders: Existing shareholders may view the significant insider selling negatively, potentially leading to decreased confidence and downward pressure on the stock price.
• Potential Investors: May be deterred by the large divestment from a major institutional investor and director.

Next Steps

• The filing does not explicitly mention any future actions, events, or milestones for Fulcrum Therapeutics or RA Capital Management beyond the reporting of these past transactions.

Key Dates

Recommendation

The substantial sale of over 4.1 million shares by a 10% owner and director, RA Capital Management, signals a significant reduction in their stake and could be interpreted as a loss of conviction or a strategic reallocation of capital away from Fulcrum Therapeutics. While executed under a 10b5-1 plan, the sheer volume of shares sold by a well-regarded institutional investor is a strong negative indicator that could lead to downward pressure on the stock price. Investors should consider this significant insider selling as a potential red flag and evaluate their holdings accordingly.

Keywords

Fulcrum Therapeutics, FULC, RA Capital Management, Insider Sale, Form 4, Beneficial Ownership, Stock Transaction, Biotechnology, Healthcare Investment, 10b5-1 Plan